Similarly to TET2, MPN patients are more likely to present with PV when JAK2V617F is acquired before DNMT3A mutation, while patients who first acquired DNMT3A mutations more commonly develop an ET phenotype [52]. Here, DNMT3A is linked to myeloproliferative disorder.